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ABSTRACT
Currently, various drugs have been found to induce many oral lesions. Some medications used to treat systemic
diseases can affect the oral mucosa and induce lesions known as oral lichenoid drug reaction (OLDR). The diagnosis
is made when the oral lesion errupted after the patient took a specific medication. However, diagnosis is challenging
when a patient takes multiple medications and the onset of the eruption is unclear. OLDRs commonly cause severe
pain in the oral cavity and affect the quality of life. Statins are widely used by patients with cardiovascular disease
(CVD) to lower blood cholesterol levels, decreasing the risk of heart attack or stroke. This review will focus the
side effects of a hypolipidemic drug group (statins) in the oral cavity. From previous experience, simvastatin may
be related to severe oral ulcerations, dysplasia, and carcinoma in situ in the oral mucosa. Moreover, simvastatin
combined with amlodipine can induce more severe oral lesions that are very difficult to treat. Therefore, the beneficial
effect of these drugs and their side effects should be considered carefully, because simvastatin significantly affects
oral and general health.
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INTRODUCTION
The use of medications is increasing due to many
patients with systemic diseases. Adverse reactions to
medications are common and have a variety of clinical
presentations in the oral cavity, the most common
being xerostomia, lichenoid reactions, ulcers, bullous
disorders, pigmentation, fibrovascular hyperplasia,
white lesions, dysesthesia, osteonecrosis, infection,
angioedema, and malignancy.1
Simvastatin
Hypolipidemic drugs, such as the statins, are widely
used medications that are beneficial for patients
with cardiovascular disease (CVD), but are less well
established for primary prevention in asymptomatic
patients. 2 The statins are a group of drugs that
successfully lower blood cholesterol levels, decreasing
the risk of heart attack or stroke. In recent years,
statins, which are made from the fungus Aspergillus
terreus, also have been reported to have other biological
activities and numerous potential therapeutic uses.3
Simvastatin is a lipid-lowering medication that is a
hydroxymethyl-glutaryl-coenzyme A (HMG-CoA)
reductase inhibitor.4

Simvastatin and oral lichenoid drug reaction
Roger et al.5 first reported the side effects of simvastatin
in 1994, describing that it induced lichenoid drug
eruption on the skin and oral mucosa. The diagnosis of
oral lichenoid drug reaction (OLDR) is sometimes very
difficult when a patient takes multiple medications.
However, history taking regarding the duration of
medications taken and that the oral lesion erupted
after using a specific drug is helpful in the diagnosis.
Moreover, Naranjo et al.6 designed a questionnaire to
determine the likelihood of whether an adverse drug
reaction has occurred. This questionnaire is useful
during history taking from patients suspected to have
OLDR.
Severe OLDR can cause pain in the oral cavity and
definitely affects quality of life and general health. Our
experience in the Oral Medicine Clinic at the Faculty of
Dentistry, Chulalongkorn University is the combination
of simvastatin and amlodipine can induce more severe
oral ulceration and OLDR. After stopping simvastatin,
the severe oral lesions gradually resolve (Figure 1A–C).
Moreover, when simvastatin is used together with
many medications, the severe oral lesions are very
difficult to treat and manage (Figure 2A–D). Therefore,
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hypolipidemic drugs, such as the statins, were the most
commonly used medication in eight of nine elderly
patients (88.9%) with red and white lesions that were
serum ANA–positive.8
Figure 1. (A) Reticular and erythematous lesions on the
palate in a 56-year-old male erupted after taking simvastatin
and amlodipine for 7–8 months before treatment. (B)
Improvement shown after stopping simvastatin and treating
the lesions with triamcinolone acetonide 0.1% mouthwash
for 3 weeks. (C) The palatal lesion resolved 7 months after
treatment.

Figure 2. (A–D) Severe oral lichenoid drug reaction in a
62-year-old patient with a history of hypertension, stroke,
dyslipidemia, and epilepsy who was taking amlodipine,
simvastatin, acetylsalicylic acid, and clopidogrel. Poor oral
hygiene and generalized severe ulceration, white striae, and
erosion with a pseudomembranous cover can be seen.
Hypothesis
Some medications eg.
Hypolipidemics/ Antihypertensives, etc.

Oral lichenoid drug reaction
Chronic irrtation/ inflammation/
poor oral hygiene/ carcinogen/oncogenes expression/ageing patients

Dysplasia

Oral squamous cell carcinoma
Figure 3. A hypothesis on the relationship between
medications, OLDR, chronic irritation, inf lammation,
poor oral hygiene, carcinogens, oncogene expression, and
aging patients who may suffer dysplasia and squamous cell
carcinoma.

simvastatin can be withdrawn when the patient’s
cholesterol level is not high or is in the borderline range.
The result of discontinuing simvastatin that induced
erosive lichenoid lesions on the lower labial mucosa
were included in the textbook Oral and Maxillofacial
Pathology.7 Interestingly, a previous study showed that

Because of their potential for OLDR development,
lists of medications that can induce OLDR should be
referred to oral medicine specialists and physicians
for consideration when managing a suspected OLDR
lesion.9 Withdrawal or replacement of the suspected
drug with other medications is recommended. In fact,
when a patient is using one medication only, it is not
difficult to replace it with another and the oral lesion
should resolve completely.10 Managing a patient with
OLDR is challenging and requires cooperation from
the physician to understand the medications that caused
the oral lesions. Cooperation between oral medicine
specialists and physicians has been useful in managing
these complicated cases. In severe cases, symptomatic
treatment and determining the cause of the lesions
are helpful in improving quality of life and general
health. Antihypertensive drugs, such as amlodipine, a
long-acting calcium channel blocker, also are widely
used. However, the interaction between simvastatin and
amlodipine is unresolved. Clinical trials have shown
that simultaneous administration of simvastatin and
amlodipine can increase simvastatin bioavailability.11
With increasing use of HMG-CoA reductase inhibitors,
the association between OLDR and these drugs should
be considered carefully. Interestingly, a previous report
suggested that, apart from their beneficial effect, statins
might be implicated in the development of oral lichenoid
lesions, moderate dysplasia, and carcinoma in situ of
the oral mucosa in an aging patient.12 Longstanding
OLDR lesions caused by various factors may possibly
transform to oral malignancy in the future (Figure 3).13
To our knowledge, few reports exist of simvastatin
inducing severe oral ulceration or OLDR. Furthermore,
red and/or white lesions in the oral mucosa must be
considered and correctly diagnosed, particularly
in older patients. Early diag nosis and proper
management can prevent unfavorable outcomes of
those patients. Although statins currently are the
preferred pharmaceutical intervention for reducing
the probability of CVD, statin-associated autoimmune
myopathy exists as a rare side effect. Recently, the
very interesting case of a 69-year-old man with early
onset diabetes mellitus precipitated by a small dose of
simvastatin highlighted the potential role of statins as
triggers of an immune system disease, statin-induced
dermatomyositis. This disease is rare and extremely
unusual adverse event associated with simvastatin
use and very few fatal cases have been reported.
Nevertheless, rare cases can take a lethal course.14
Further investigation into the mechanism and side
effects of these drugs will be useful for patients because
these drugs are widely used in the general population.
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CONCLUSION
Various medications have side effects that range
from mild to severe, including eruption of severe
oral lesions. These lesions, such as generalized oral
ulcerations, can cause pain and suffering in the oral
cavity. Simvastatin commonly is taken by patients
with hypercholesterolemia. However, for those with
borderline cholesterol levels, an alternative treatment
should be recommended, such as weight control or
avoiding high-fat food consumption to prevent the
untoward effects that can occur when taking this drug.
Simvastatin alone or in combination with amlodipine
or other drugs should be investigated further for the
possible interaction of side effects to the oral mucosa.
Severe and painful oral lesions affect oral hygiene
and quality of life in these patients. Moreover, oral
mucosal changes are an indicator of oral and general
health. Therefore, oral medicine specialists, physicians,
and dentists can have important roles, prevent the side
effects of these drugs in the oral cavity, and possibly
save the patient’s life. Further studies on these drugs
may be important for oral and global heath.
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